Sensorineural therapeutics - Otonomy
Latest Information Update: 19 Nov 2015
At a glance
- Originator Unknown
- Developer Otonomy
- Mechanism of Action Neurotransmitter stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sensorineural hearing loss
Most Recent Events
- 10 Nov 2015 Preclinical trials in Sensorineural hearing loss in USA (unspecified route)